TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Autologous Fat Grafting on Acute Burn Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* both males and females within the age frame are candidates.~* previously healthy individuals with no co-morbid conditions e.g cardiac, hepatic, diabetic, vascular or renal disease.~* with TBSA of 10 to 30% affected and of deep dermal to full thickness wound depth, at any part of the body except the genitalia, perineum or the perianal region or those with inhalational injury.~Exclusion Criteria:~* other patients aged younger or older than the specified age group.~* patients with co-morbid conditions.~* patients with smaller or larger BSA than the specified BSA.~* burns involving the genitalia, perineum or the perianal region and patients with inhalational injury.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: PLACEBO_COMPARATOR): this group of patients are treated with the regular conventional methods like application of topical agents e.g silver sulphadiazine
- fat grafting group (Type: ACTIVE_COMPARATOR): this group of patients will have the autologous fat grafting for their burn wounds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults at least 18 years of age~* Has advanced (unresectable Stage III) or metastatic (Stage IV) melanoma that is BRAF mutation positive (V600E)~* Is treatment naive for advanced (unresectable) or metastatic melanoma, with the exception of Interleukin 2 (IL-2) which is allowed.~* Has measurable disease according to RECIST 1.1 criteria.~* Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment.~* Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication.~* Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication.~* Must have adequate organ function.~* Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.~Exclusion Criteria:~* Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy or surgery).~* Evidence of active central nervous system (CNS) disease.~* Previous treatment for metastatic melanoma, including treatment with BRAF or MEK inhibitor.~* A history of other malignancy. Subjects who have been disease-free for 5 years or subjects with a history of complete resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* History of Human Immunodeficiency Virus (HIV) infection.~* Certain cardiac abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK2118436 (Type: EXPERIMENTAL): Subjects in this arm will receive GSK2118436 150 mg twice daily.
- Dacarbazine (DTIC) (Type: ACTIVE_COMPARATOR): Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
- Crossover (Type: EXPERIMENTAL): Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A woman between, and including, 10 and 14 years of age at the time of the first vaccination.~Written informed consent from the subject prior to enrolment. Subject must be free of obvious health problems. Subject must have negative urine pregnancy test.~Exclusion Criteria:~Pregnant or breastfeeding. Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality.~History of chronic condition(s) requiring treatment such as cancer, chronic hepatitis or kidney disease(s), diabetes, or autoimmune disease.~Previous vaccination against human papillomavirus (HPV).

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written consent and assent as required~* Diagnosis of MPS 1 confirmed by clinical signs and symptoms, documented fibroblast or leukocyte IDUA enzyme activity of less than 10% the lower limit of normal~* Female patients must not be pregnant, willing to utilize appropriate birth control methods and undergo pregnancy testing during the study~* if taking standard ERT, must be willing to discontinue for 1 week prior to dosing and for the study duration~Additional Inclusion Criteria, Stage 1:~* 18 years of age or older~* must have a diagnosis of Hurler-Scheie or Scheie syndrome~Additional Inclusion Criteria, Stage 2:~* 2 years of age or older (and less than 18)~* must be willing to undergo CNS testing, including assessment of CSF via lumbar puncture, MRI scans and neurocognitive testing~* must have evidence of Hurler-Scheie or Scheie with CNS involvement, as evidence by:~* score of 1 to 3 standard deviations below mean on IQ testing (i.e. IQ=55 or more) or in one domain of neuropsychological function (language, memory, non-verbal ability) OR~* documented historical evidence of a decline greater than 1 standard deviation on sequential testing, OR~* score between 0.75 and 1 standard deviation below the mean, AND cognitive deficit affects daily performance~Exclusion Criteria:~* Refusal to complete all assessments~* Pregnant or Lactating~* Received investigational drug within 1 year prior to study enrollment~* Medical condition or extenuating circumstance that, in the opinion of the investigator, may interfere with study compliance~* CSF pressure greater than 25 cm H20 (18 mm Hg)~* Known hypersensitivity to alpha-L-iduronidase (IDUA/Aldurazyme) or any components/excipients found in AGT-181~* Previous successful (engrafted) hematopoietic stem cell transplantation which has resulted in normalization of urinary glycosaminoglycans (GAGs); or major organ transplantation~* Clinically significant spinal cord compression or evidence of cervical instability (i.e. expected to require intervention during study participation)~* History of diabetes mellitus or hypoglycemia~Additional Exclusion Criteria, Stage 2:~* Has ventriculoperitoneal shunt~* IQ below 55~* Previously received AGT-181 in Stage 1 of the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage 1 (adult) (Type: EXPERIMENTAL): AGT-181
- Stage 2 (children) (Type: EXPERIMENTAL): AGT-181

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of Porphyria Cutanea Tarda based on clinical exam and 24-hour urine porphyrin levels~* have Porphyria Cutanea Tarda for at least 3 months prior to enrollment with active blistering (3 blisters or erosions per month)~* women of childbearing potential must use an effective method of contraception during the study, however this cannot include hormonal contraception (oral contraceptives, hormone patches, Depo-Provera injections, NUVA Ring, etc.)~* treatment naive patients or patients unresponsive or intolerant of phlebotomy~* Ferritin level is greater than or equal to 25ng/mL~Exclusion Criteria:~* patients with serum creatinine above the upper limit of normal~* patients receiving phlebotomy who are controlled on this therapy~* pregnant or breast feeding females~* patients with liver transaminases more than 5 times the upper limit of normal~* patients with a history of hypersensitivity to deferasirox~* patients with a history of pre-existing renal condition, or receiving medication that depresses renal function~* patients on other chelators~* history of non-compliance to medical regimens.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's Disease (PD) diagnosed between the ages of 30 and 85 years;~* Hoehn and Yahr Stage 1-3 in an on state;~* Require levodopa-containing medication regimen at least 3 times during the waking day;~* Experience motor fluctuations with a minimum of 2 hours of average daily off time per waking day (excluding early morning off time) and demonstrate levodopa responsiveness;~* Are on stable PD medication regimen;~* Total daily LD dose \<1600 mg/day;~* Able to perform a spirometry maneuver in the ON and OFF states;~* Normal cognition confirmed by MMSE score ≥25~Exclusion Criteria:~* Pregnant or lactating females;~* Previous surgery for PD or plan to have stereotactic surgery during the study period;~* History of psychotic symptoms requiring treatment, or suicide ideation or attempt within last year;~* Known contraindication to the use of levodopa;~* Any significant condition, severe concurrent disease, abnormality or finding that would make patients unsuitable or may compromise patient safety;~* Any contraindication to performing routine spirometry.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CVT-301 Low Dose (Type: EXPERIMENTAL): Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
- CVT-301 High Dose (Type: EXPERIMENTAL): Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
- Placebo (Type: PLACEBO_COMPARATOR): Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Inclusion Criteria for Part I:~  * Must have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS).~ * Must have a baseline Expanded Disability Status Scale (EDSS) score between 0.0 and 5.0, inclusive.~Key Inclusion Criteria for Part II:~• Subjects who participated in and completed Part I per protocol.~Key Exclusion Criteria:~* Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease.~* Pregnant or nursing women.~NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Part I Placebo (Type: PLACEBO_COMPARATOR): Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID.
- Part I BG00012 (Type: EXPERIMENTAL): BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
- Part II BG00012 (Type: EXPERIMENTAL): Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Macular Pigment and Glare Disability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gender: male or female~* Age: 18 - 40 years~* BMI: 20-30~* No anticipated changes in dieting habits (as relevant to xanthophyll intake).~* No anticipated surgical procedures.~* Assessed as healthy, based on a pre-study examination including medical history, physical examination, and clinical laboratory. The examination will be performed by an MD or a Nurse Practitioner.~* Willingness and ability to give written informed consent and willingness and ability to comply with the study requirements.~* Corrected visual acuity (ETDRS): better than 20/60~Exclusion Criteria:~* BMI \<20 or \>30~* Age \<18 or \>40 years~* Smokers~* Current or history of relevant diseases (such as AMD)~* Corrected visual acuity worse than 20/60~* Inability to reliably perform MPOD measurements by heterochromatic flicker photometry or any of the other ophthalmic tests of the study.~* Any condition likely to interfere with normal gastro-intestinal absorption of xanthophylls.~* Current use of xanthophyll containing supplements~* Use of xanthophyll containing supplements in the past 6 months~* Participation in any other study during last 1 month.~* Blood donation during the last 3 months.~* Known hypersensitivity or allergy to xanthophylls.~* Regular intake of medications or supplements, which the principal investigator deems likely to confound the study outcomes.~* Suspected lack of compliance with any requirements of the study.~* Childbearing potential and unwillingness to refrain from acceptable anticonceptive measures (not including abstinence).~* Current pregnancy or breast feeding~* Any relevant abnormalities in the routine laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
- Placebo (Type: PLACEBO_COMPARATOR): visually identical placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be willing to use 2 methods of effective contraception~* Must have venous access~* Must be willing to forego participation in other clinical trials for SLE.~Exclusion Criteria:~* Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product~* Major surgery within 8 weeks before signing informed consent form (ICF)~* Elective major surgery planned during the study period~* Concomitant Medications within the last 12 weeks: Azathioprine \> 200 mg/day, Mycophenolate mofetil/mycophenolic acid \> 2.0 g/day, oral, subcutaneous, or intramuscular methotrexate \> 25 mg/week~* A live or attenuated vaccine within 4 weeks of signing the ICF~* Bacillus of Calmette and Guérin (BCG) vaccine within 1 year of ICF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Anifrolumab (Type: EXPERIMENTAL): Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of HLA-B27 positive related uveitis in non- acute phase~* At least one autoimmune uveitis relapse~Exclusion Criteria:~* Use of supplements (nutraceuticals) or systemic therapy for uveitis with anti-inflammatory immunosuppressive or biological drugs within last 30 days~* Anticipated need for systemic anti-inflammatory treatment during the study~* Use of intravitreal peribulbar, sub-tenon, periocular injection in the previous 6 months~* Long-term treatment with a systemic anti-inflammatory, immune suppressant drugs~* Woman taking hormonal contraceptives, pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Norflo Oro (Type: EXPERIMENTAL): The study subject will take the entire content of one packet of Norflo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.
- Placebo for Norflo Oro (Type: PLACEBO_COMPARATOR): The study subject will take the entire content of one packet of Placebo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Administration of Virus-Specific Cytotoxic T-Lymphocytes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of allogeneic (i.e. HLA matched or mismatched related or unrelated) donor stem cell transplants at risk for Adenoviral disease~* No evidence of GVHD \> Grade II at time of enrollment~* Life expectancy \> 30 days~* No severe intercurrent infections~* Lansky/Karnofsky scores \>60~* Absence of severe renal disease (Creatinine \> x 3 normal for age)~* Absence of severe hepatic disease (direct bilirubin \> 3 mg/dl or SGOT \> 500)~* Patient must be at least 30 days post transplant to be eligible to receive CTL~* Not receiving Cidofovir~* Patient has not received other viral specific CTL prophylactically within 4 weeks of receiving Adv-CTL~* Patient/guardian able to give informed consent~Exclusion Criteria:~* Patients with GVHD Grades III-IV~* Patients with hepatic or renal disease as specific above~* Patient has received other viral specific CTL (e.g. EBV-specific CTL or CMV-specific CTL) within 4 weeks of receiving Adv-CTL~* Patients with Adenoviral disease prior to day +30 post transplant Adenoviral diseases defined as the presence of more than two sites positive for adenovirus by culture~* Patients with less than 50% donor chimerism in either peripheral blood or bone marrow or patients with relapse of original disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virus Specific Cytoxic T lymphocytes (Type: EXPERIMENTAL): Virus Specific Cytoxic T lymphocytes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete